Woodcock: The US FDA Sets The Stage For Global Quality Dossiers

New approach could eliminate minor differences among authorities, enabling pharmaceutical manufacturing processes to become truly global.

FDABldg1ExteriorWithCircle_1200x675
global quality dossier starts with the US FDA's 'cloud'

The US Food and Drug Administration has been quietly laying the groundwork for what Janet Woodcock, director of the agency’s Center for Drug Evaluation and Research, sees as the only way to resolve the growing problem of conflicting international pharmaceutical manufacturing quality requirements – establishing a global quality dossier.

More from Manufacturing

Will They Or Won’t They? Tariff Questions Loom For Drugmakers

 

Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.

Gene Therapy ‘Survival Of The Fittest’ – Why Companies Need To Understand Health Systems

 

Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.

Global Pilot Reduces Drug Manufacturing Inspections With Hybrid Approach

 
• By 

A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.

UK MHRA Prepares To Roll-Out Decentralized Manufacturing Framework

 
• By 

The UK’s medicines regulator is pressing on with clarifying its expectations on decentralized manufacturing of medicines.

More from Compliance

Global Pilot Reduces Drug Manufacturing Inspections With Hybrid Approach

 
• By 

A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.

UK MHRA Prepares To Roll-Out Decentralized Manufacturing Framework

 
• By 

The UK’s medicines regulator is pressing on with clarifying its expectations on decentralized manufacturing of medicines.

How To Leverage US FDA’s ‘Consistent With Labeling’ Guidance In DTC Ads

 
• By 

Sponsors should review longstanding agency concepts on consumer-friendly language and claims limitations, along with Office of Prescription Drug Promotion research and enforcement, when applying the 2018 CFL guidance to direct-to-consumer advertising, Sidley Austin’s Cope says.